Molecular mechanism of action for reversible P2Y12 antagonists

被引:9
|
作者
Liu, Haibo [2 ]
Ge, Hu [1 ]
Peng, Yong [2 ]
Xiao, Peigen [2 ]
Xu, Jun [1 ]
机构
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll, Inst Med Plant Dev, Beijing 100194, Peoples R China
关键词
P2Y(12) receptor; ADP; Antagonists; Platelets aggregation; SWISS-MODEL REPOSITORY; CLOPIDOGREL PLUS ASPIRIN; ANTIPLATELET THERAPY; RECEPTOR ANTAGONIST; COST-EFFECTIVENESS; P2; RECEPTORS; FREE-ENERGY; PROTEIN; PREVENTION; P2Y12;
D O I
10.1016/j.bpc.2011.03.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently, reversible antagonists of the P2Y(12) receptor have been reported. However, the mechanisms of binding have not been elucidated. To this end, a number of homology models were built by means of three programs from four templates. A consensus model was derived from those initial models. The final model was created by refining the consensus model with molecular dynamics simulations. The agonist and antagonists of P2Y(12) have been docked in the final model. For the agonist, the Arg256, Lys280, and Phe252 are "hot" residues. For the antagonists, the Lys280 and Phe252 are "hot" residues that have hydrogen bonding contacts and pi-pi interactions, respectively. These results can explain the observations of mutation experiments and can guide the design of new inhibitors. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:74 / 81
页数:8
相关论文
共 50 条
  • [31] Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists
    Schilling, Uta
    Dingemanse, Jasper
    Ufer, Mike
    CLINICAL PHARMACOKINETICS, 2020, 59 (05) : 545 - 566
  • [32] The Role and Molecular Mechanism of P2Y12 Receptors in the Pathogenesis of Atherosclerotic Cardiovascular Diseases
    Wang, Lu
    Wang, Jinxuan
    Xu, Jianxiong
    Qin, Weixi
    Wang, Yuming
    Luo, Shisui
    Wang, Guixue
    APPLIED SCIENCES-BASEL, 2021, 11 (19):
  • [33] Efficacy and Safety of Ticagrelor: A Reversible P2Y12 Receptor Antagonist
    Anderson, Shawn D.
    Shah, Niren K.
    Yim, Juwon
    Epstein, Benjamin J.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (03) : 524 - 537
  • [34] Platelet function assays that assess response to P2Y12 antagonists vary widely in their sensitivities to low levels of P2Y12 receptor blockade
    Judge, H. M.
    Buckland, R. J.
    Sugidachi, A.
    Jakubowski, J. A.
    Storey, R. F.
    EUROPEAN HEART JOURNAL, 2008, 29 : 835 - 835
  • [35] Adenine mono- and dinucleotides modified with lipophilic acetal and urea moieties as reversible P2Y12 antagonists.
    Douglass, JG
    Patel, RI
    Redick, CC
    Jones, AC
    Shaver, SR
    Boyer, JL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 227 : U54 - U54
  • [36] Molecular mechanisms of action of thiol reagents at the human platelet P2Y12 receptor.
    Algaier
    von Kuegelgen, I.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2007, 375 : 27 - 27
  • [37] Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
    Giossi, A.
    Pezzini, A.
    Del Zotto, E.
    Volonghi, I.
    Costa, P.
    Ferrari, D.
    Padovani, A.
    CURRENT DRUG TARGETS, 2010, 11 (03) : 380 - 391
  • [38] Effective and Safe Transition Between Intravenous and Oral P2Y12 Antagonists
    Schneider, David J.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2023, 16 (20) : 2540 - 2541
  • [39] Emerging P2Y12 Receptor Antagonists: Role in Coronary Artery Disease
    Oliphant, Carrie S.
    Doby, J. Bradford
    Blade, Crystal L.
    Das, Kanak
    Mukherjee, Debabrata
    Das, Pranab
    CURRENT VASCULAR PHARMACOLOGY, 2010, 8 (01) : 93 - 101
  • [40] Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists
    De Labriolle A.
    Doazan J.P.
    Lemesle G.
    Bonello L.
    Current Cardiology Reports, 2011, 13 (5) : 439 - 450